Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Acta Biomater. 2020 Oct 29;119:155–168. doi: 10.1016/j.actbio.2020.10.042

Figure 8. Engraftment of engineered tissues from culturing XF-hiPSC-VSMCs on PGA scaffolds.

Figure 8.

Results suggested that engineered vascular tissues developed using XF-hiPSC-VSMCs presented similar histological properties to those from XG-hiPSC-VSMCs after subcutaneous implantation into immune-deficient mouse model.

(A) Schematic illustration for subcutaneously engrafting engineered tissue from XF-hiPSC-VSMCs-P grown on PGA scaffolds. Scale bar: 5 mm.

(B) Morphology of the explanted engineered tissues on day 14 post-engraftment.

(C) H&E staining, Masson’s trichrome staining and immunofluorescent staining (CNN1, human leukocyte antigen-A [HLA-A], α-SMA and MYH11) of the explanted engineered tissues made from XF- or XG-hiPSC-VSMCs-P under xenogeneic-free or xenogeneic conditions, respectively, or blank control PGA meshes without seeded cells. DNA (nuclear) was counterstained by DAPI in immunostaining. Red arrow heads indicate PGA remnants. White lines indicate the border between the engrafted and host tissues. Scale bar: 100 μm.